ARTICLE SUMMARY:
The five most-read MedTech Strategist articles posted in September to MyStrategist.com cover build-to-buy projects in medtech, an interview with Cannacord's Kyle Rose on orthopedic industry trends, and a look at recent funding rounds for femtech companies.
The top five MedTech Strategist September articles, based on readers’ views.
Subscribers, click through to read the full articles. Non-subscribers, take advantage of our free trial offer.
#1: Medtronic and the Value of Build-to-Buy
Build-to-buy projects, in which small companies and entrepreneurs work closely from the very beginning with large strategics to develop technology that the big companies will, hopefully, acquire is the latest iteration of a trend in medtech: a closer engagement of big and small companies. A conversation with Medtronic’s Chris Eso.
#2: Half Moon and the Case for Transcatheter Mitral Valve Repair
Transcatheter mitral valve technology represents one of the most promising markets in medtech, likely even surpassing that of aortic transcatheter devices. But so far, no consensus has emerged on the optimum approach. Half Moon Medical, a novel build-to-buy project that brings together The Foundry and Medtronic, is making the case for repair rather than replacement.
#3: Canaccord's Kyle Rose Previews Innovation, COVID-Era Uncertainty at Upcoming AAOS
In this video interview, leading Wall Street medtech analyst Kyle Rose of Canaccord Genuity speaks with us about orthopedic industry trends and innovation as the American Academy of Orthopedic Surgeons gets underway in San Diego on August 31, one of the first major medical meetings to go live since the pandemic began.
#4: Women’s Health Enjoys a Tsunami of Investment
Women’s health has been the target of several enormous funding rounds recently. While focused on femtech, these deals are also about the power of technology, subscription-based business models, and new kinds of payors to solve problems in healthcare delivery as a whole.
#5: AAOS Explores a Post-COVID Return to Normal. It Won’t Be Easy
As a prolonged pandemic takes its toll, a subdued AAOS met to look ahead at the impact of regulatory and reimbursement changes on different aspects of orthopedics, including orthobiologics and the scientific advances that are rapidly changing the regenerative medicine field.
Trial MyStrategist.com
and unlock 7-days of exclusive
subscriber-only access
to the medical device industry's most trusted strategic publications:
MedTech Strategist
&
Market Pathways
. For more information on our demographics and current readership
click here
.